Aspirin for the Primary Prevention of Stroke and Myocardial Infarction: Ineffective or Wrong Dose?

American Journal of Medicine

Volumn 123, Issue 2, 2010, Pages 101-102

  Dalen, James E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HEART INFARCTION; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; STROKE; TREATMENT FAILURE;

ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 74549176008     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.11.001     Document Type: Editorial

References (17)

1. Soni A. Aspirin use among the Adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005 (July, 2007), Agency for Healthcare Research and Quality
2. Dalen J.E. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med. 119 (2006) 198-202
3. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing physicians' health study. N Engl J Med. 321 (1989) 129-135
4. Becker R.C., Meade T.W., Berger P.B., et al. The primary and secondary prevention of coronary artery disease. Chest 133 (2008) 776S-814S
5. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol. 52 (2008) 1502-1517
6. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med. 150 (2009) 396-404
7. American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=4704 Accessed October 28, 2009
8. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA 300 (2008) 2134-2141
9. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) a1840
10. Fowkes G. Aspirin for asymptomatic atherosclerosis trial. Presented at European Society of Cardiology 2009 Congress, August 30, 2009, Barcelona, Spain.
11. Hiatt W.R. Aspirin for prevention of cardiovascular events. BMJ 337 (2008) a1806
12. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
13. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Lancet 296 (1988) 313-316
14. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 351 (1998) 233-241
15. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
16. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357 (2001) 89-95
17. Ridker P.M., Cook N.R., Min Lee I., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 353 (2005) 1293-1304